These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

1963 related articles for article (PubMed ID: 29414288)

  • 1. Comparison of myelin oligodendrocyte glycoprotein (MOG)-antibody disease and AQP4-IgG-positive neuromyelitis optica spectrum disorder (NMOSD) when they co-exist with anti-NMDA (N-methyl-D-aspartate) receptor encephalitis.
    Fan S; Xu Y; Ren H; Guan H; Feng F; Gao X; Ding D; Fang F; Shan G; Guan T; Zhang Y; Dai Y; Yao M; Peng B; Zhu Y; Cui L
    Mult Scler Relat Disord; 2018 Feb; 20():144-152. PubMed ID: 29414288
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Neuromyelitis optica spectrum disorders with antibodies to myelin oligodendrocyte glycoprotein or aquaporin-4: Clinical and paraclinical characteristics in Algerian patients.
    Bouzar M; Daoudi S; Hattab S; Bouzar AA; Deiva K; Wildemann B; Reindl M; Jarius S
    J Neurol Sci; 2017 Oct; 381():240-244. PubMed ID: 28991690
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Myelin-oligodendrocyte-glycoprotein (MOG) autoantibodies as potential markers of severe optic neuritis and subclinical retinal axonal degeneration.
    Havla J; Kümpfel T; Schinner R; Spadaro M; Schuh E; Meinl E; Hohlfeld R; Outteryck O
    J Neurol; 2017 Jan; 264(1):139-151. PubMed ID: 27844165
    [TBL] [Abstract][Full Text] [Related]  

  • 4. AQP4-IgG-seropositive neuromyelitis optica spectrum disorder (NMOSD) coexisting with anti-N-methyl-D-aspartate receptor (NMDAR) encephalitis: A case report and literature review.
    Tao S; Zhang Y; Ye H; Guo D
    Mult Scler Relat Disord; 2019 Oct; 35():185-192. PubMed ID: 31398657
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Neuromyelitis optica spectrum disorders with aquaporin-4 and myelin-oligodendrocyte glycoprotein antibodies: a comparative study.
    Kitley J; Waters P; Woodhall M; Leite MI; Murchison A; George J; Küker W; Chandratre S; Vincent A; Palace J
    JAMA Neurol; 2014 Mar; 71(3):276-83. PubMed ID: 24425068
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Clinical Characteristics of Anti-
    Zhang S; Yang Y; Liu W; Li Z; Li J; Zhou D
    Front Immunol; 2022; 13():857443. PubMed ID: 35837405
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The clinical value of complement proteins in differentiating AQP4-IgG-positive from MOG-IgG-positive neuromyelitis optica spectrum disorders.
    Qin C; Chen B; Tao R; Chen M; Ma X; Shang K; Wu LJ; Wang W; Bu BT; Tian DS
    Mult Scler Relat Disord; 2019 Oct; 35():1-4. PubMed ID: 31276911
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Clinicoradiological comparative study of Aquaporin-4-IgG seropositive neuromyelitis optica spectrum disorder (NMOSD) and MOG antibody associated disease (MOGAD): A prospective observational study and review of literature.
    Nagireddy RBR; Kumar A; Singh VK; Prasad R; Pathak A; Chaurasia RN; Mishra VN; Joshi D
    J Neuroimmunol; 2021 Dec; 361():577742. PubMed ID: 34655992
    [TBL] [Abstract][Full Text] [Related]  

  • 9. MOG-IgG in NMO and related disorders: a multicenter study of 50 patients. Part 1: Frequency, syndrome specificity, influence of disease activity, long-term course, association with AQP4-IgG, and origin.
    Jarius S; Ruprecht K; Kleiter I; Borisow N; Asgari N; Pitarokoili K; Pache F; Stich O; Beume LA; Hümmert MW; Trebst C; Ringelstein M; Aktas O; Winkelmann A; Buttmann M; Schwarz A; Zimmermann H; Brandt AU; Franciotta D; Capobianco M; Kuchling J; Haas J; Korporal-Kuhnke M; Lillevang ST; Fechner K; Schanda K; Paul F; Wildemann B; Reindl M;
    J Neuroinflammation; 2016 Sep; 13(1):279. PubMed ID: 27788675
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Comparison of clinical characteristics and prognoses in patients with different AQP4-Ab and MOG-Ab serostatus with neuromyelitis optica spectrum disorders.
    Du Q; Shi Z; Chen H; Zhang Y; Wang J; Qiu Y; Zhao Z; Zhang Q; Zhou H
    J Neuroimmunol; 2021 Apr; 353():577494. PubMed ID: 33515897
    [TBL] [Abstract][Full Text] [Related]  

  • 11. A rare concurrence: Antibodies against Myelin Oligodendrocyte Glycoprotein and N-methyl-d-aspartate receptor in a child.
    Sarigecili E; Cobanogullari MD; Komur M; Okuyaz C
    Mult Scler Relat Disord; 2019 Feb; 28():101-103. PubMed ID: 30590238
    [TBL] [Abstract][Full Text] [Related]  

  • 12. MOG-IgG in NMO and related disorders: a multicenter study of 50 patients. Part 2: Epidemiology, clinical presentation, radiological and laboratory features, treatment responses, and long-term outcome.
    Jarius S; Ruprecht K; Kleiter I; Borisow N; Asgari N; Pitarokoili K; Pache F; Stich O; Beume LA; Hümmert MW; Ringelstein M; Trebst C; Winkelmann A; Schwarz A; Buttmann M; Zimmermann H; Kuchling J; Franciotta D; Capobianco M; Siebert E; Lukas C; Korporal-Kuhnke M; Haas J; Fechner K; Brandt AU; Schanda K; Aktas O; Paul F; Reindl M; Wildemann B;
    J Neuroinflammation; 2016 Sep; 13(1):280. PubMed ID: 27793206
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Quantitative brain lesion distribution may distinguish MOG-ab and AQP4-ab neuromyelitis optica spectrum disorders.
    Yang L; Li H; Xia W; Quan C; Zhou L; Geng D; Li Y
    Eur Radiol; 2020 Mar; 30(3):1470-1479. PubMed ID: 31748853
    [TBL] [Abstract][Full Text] [Related]  

  • 14. [Clinical analysis of neuromyelitis optica spectrum disorders in childhood].
    Zhou J; Zhang Y; Ji TY; Jin YW; Bao XH; Zhang YH; Xiong H; Chang XZ; Jiang YW; Wu Y
    Zhonghua Er Ke Za Zhi; 2019 Feb; 57(2):118-124. PubMed ID: 30695886
    [No Abstract]   [Full Text] [Related]  

  • 15. Spinal cord lesions and atrophy in NMOSD with AQP4-IgG and MOG-IgG associated autoimmunity.
    Chien C; Scheel M; Schmitz-Hübsch T; Borisow N; Ruprecht K; Bellmann-Strobl J; Paul F; Brandt AU
    Mult Scler; 2019 Dec; 25(14):1926-1936. PubMed ID: 30475082
    [TBL] [Abstract][Full Text] [Related]  

  • 16. MOG-IgG in NMO and related disorders: a multicenter study of 50 patients. Part 3: Brainstem involvement - frequency, presentation and outcome.
    Jarius S; Kleiter I; Ruprecht K; Asgari N; Pitarokoili K; Borisow N; Hümmert MW; Trebst C; Pache F; Winkelmann A; Beume LA; Ringelstein M; Stich O; Aktas O; Korporal-Kuhnke M; Schwarz A; Lukas C; Haas J; Fechner K; Buttmann M; Bellmann-Strobl J; Zimmermann H; Brandt AU; Franciotta D; Schanda K; Paul F; Reindl M; Wildemann B;
    J Neuroinflammation; 2016 Nov; 13(1):281. PubMed ID: 27802825
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Myelin-oligodendrocyte glycoprotein antibodies in adults with a neuromyelitis optica phenotype.
    Kitley J; Woodhall M; Waters P; Leite MI; Devenney E; Craig J; Palace J; Vincent A
    Neurology; 2012 Sep; 79(12):1273-7. PubMed ID: 22914827
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Autoantibody to MOG suggests two distinct clinical subtypes of NMOSD.
    Yan Y; Li Y; Fu Y; Yang L; Su L; Shi K; Li M; Liu Q; Borazanci A; Liu Y; He Y; Bennett JL; Vollmer TL; Shi FD
    Sci China Life Sci; 2016 Dec; 59(12):1270-1281. PubMed ID: 26920678
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Effectiveness of mycophenolate mofetil as first-line therapy in AQP4-IgG, MOG-IgG, and seronegative neuromyelitis optica spectrum disorders.
    Montcuquet A; Collongues N; Papeix C; Zephir H; Audoin B; Laplaud D; Bourre B; Brochet B; Camdessanche JP; Labauge P; Moreau T; Brassat D; Stankoff B; de Seze J; Vukusic S; Marignier R;
    Mult Scler; 2017 Sep; 23(10):1377-1384. PubMed ID: 27885065
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Understanding the Antibody Repertoire in Neuropsychiatric Systemic Lupus Erythematosus and Neuromyelitis Optica Spectrum Disorder: Do They Share Common Targets?
    Mader S; Jeganathan V; Arinuma Y; Fujieda Y; Dujmovic I; Drulovic J; Shimizu Y; Sakuma Y; Stern JNH; Aranow C; Mackay M; Yasuda S; Atsumi T; Hirohata S; Diamond B
    Arthritis Rheumatol; 2018 Feb; 70(2):277-286. PubMed ID: 29073350
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 99.